LUNG CANCER PRECEPTORSHIP




17-18 NOVEMBER 2023
PULLMAN SYDNEY HYDE PARK
#TOGAPSHIP23



FRIDAY NOVEMBER 17

TIME	TOPIC	PRESENTED BY
9:00am	Registration / Morning Tea Level 1 Foyer	
10:00am	Welcome	Prof Nick Pavlakis
	Prevention, Diagnosis and Supportive Care	Chair: Prof Nick Pavlakis
10:15am	Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening (NLST)	Lyn Ley Lam
10:25am	Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial (NELSON)	Walid Zwieky
10:35am	3. Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study	Zarka Samoon
10:45am	 Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer (Temel) 	Beulah Benedict
10:55am	Discussion	
	Early-Stage NSCLC	Chair: Joanna Lee
11:15am	 Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with NO or N1 (less than hilar) non-small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial 	Sam Dunn
11:25am	6. Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer	Justin Tan
11:35am	 Video-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung Cancer (VIOLET Trial) 	Emmy Sneath
11:45am	8. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery	Maryanne Akkerman
11:55am	9. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent nodenegative non-small-cell lung cancer: an open-label, randomised, phase 2 trial (iSABR)	Emmy Sneath
12:05pm	10.Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial	Rebecca Symons
12:15pm	11.Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group	Suzanne Poulgrain
12:25pm	Discussion	




FRIDAY NOVEMBER 17

TIME	TOPIC	PRESENTED BY
12:45pm	Lunch Windows on the Park Restaurant	
	The Advent of TKIs- EGFR	Chair: Lyn Ley Lam
13:40	12.Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma (IPASS)	Zarka Samoon
13:50	13.Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (AURA3)	Yat Ming Lau
14:00	 14.Combined Review Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC (FLAURA) 	Catherine Bennett
14:10	 15.Combined Review Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer (ADAURA) Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC (ADAURA) 	Claire Harris
14:20	Discussion	
14:40	Afternoon Tea Level 1 Foyer	
	TKIs- an Expanding Field	Chair: Prof Nick Pavlakis
15:10	 16.Combined Review First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer 	Claire Mok
15:20	 17.Combined Review Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer (CROWN) 	David Cheng
15:30	 18.Combined Review KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors (CODEBREAK 100) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, openlabel, phase 3 trial (CODEBREAK 200) 	Gowri Shivasabesan

FRIDAY NOVEMBER 17


TIME	TOPIC	PRESENTED BY
15:40	 19.Combined Review Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer (LIBRETTO-001) First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC (LIBRETTO-431) 	Hsing Hwa Lee
15:50	Discussion	
16:10	Careers	Chair: Prof Nick Pavlakis
16:55	Close	Prof Nick Pavlakis
17:00	Networking Reception Level 1 Foyer	
18:00	Finish	



SATURDAY NOVEMBER 18

TIME	TOPIC	PRESENTED BY
7:30am	Networking Breakfast Ibis 2 Room	
8:30am	Welcome	Prof Nick Pavlakis
	The Advent of IO	Chair: Prof Nick Pavlakis
8:35am	20.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non- Small-Cell Lung Cancer (KEYNOTE-024)	Indika Gunadasa
8:45am	21.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial	Rebecca Symons
8:55am	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-189) Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from (KEYNOTE-189)	Sana Haider
9:05am	23.Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC (IMpower150)	Liam Dwyer
9:15am	24. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial	Matthew Cross
9:25am	25.Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer (PACIFIC)	Walid Zwieky
9:35am	Discussion	
	IO in Early Stage	Chair: Prof Nick Pavlakis
9:55am	26.Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816)	Mohammadali Ahmadipour
10:05am	27.Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer (KEYNOTE-671)	Nikita Allan
10:15am	28.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial	Rosemary David
10:25am	29.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	Sarah Childs

SATURDAY NOVEMBER 18



TIME	TOPIC	PRESENTED BY	
10:35am	Discussion		
10:55am	Morning Tea Level 1 Foyer		
	SCLC and Mesothelioma	Chair: Prof Nick Pavlakis	
11:25am	 Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) 	Syapiq Long	
11:35am	31.Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial	Ben Challis	
11:45am	32.Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial	Joanna Lee	
11:55am	33.Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial	Trisha Khoo	
12:05pm	34.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	Wade Huish	
12:15pm	35. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial (THORA)	William Moorhead	
12:25pm	Discussion		
12:45pm	Open Q and A- ask what you like!	Chair: Prof Nick Pavlakis	
13:05	Close	Prof Nick Pavlakis	
13:10	Finish		

SPONSORS

Thank you for your contribution. We gratefully acknowledge your sponsorship!





SILVER



BRONZE





Thoracic Oncology Group Australasia

PO Box 1103 Thornbury VIC 3071

Ph: +61 3 9087 3550

E: info@thoraciconcology.org.au

ABN: 47 641 984 198







